Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, available data suggest that MGF-driven restoration of redox homeostasis represents a central mechanistic axis of its antitumor activity, rather than merely a downstream branch of apoptosis (84,85).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [84]
In the citing paper
“Activation of oncogenes, aberrant metabolism, mitochondrial dysfunction, and loss of the tumor suppressor p53 can all promote increased ROS accumulation in cancer cells 69.”
From Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) · cites this paper as [69]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272 · cited 1×
“This is consistent with the high incidence of p53 mutation or loss of p53 function in over 50% of human cancer”
Background
Research works printed but not linked: 1
- Kim, G. J., Chandrasekaran, K. & Morgan, W. F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 21, 361–367 (2006). · DOI · Paper page
Cited by
Items 401–500 of 1,014
Yue, C., Yang, Y., Zhang, C., Alfranca, G., Cheng, S., Ma, L., Liu, Y., Zhi, X., Ni, J., Jiang, W., et al. (2016) · Theranostics · doi:10.7150/thno.15433 · Cited by 169
“Cancer cells exhibit greater ROS stress than normal cells, partly due to oncogenic stimulation, which increases metabolic activity and mitochondrial malfunction [4].”
BackgroundOxidative stress, cellular senescence and ageing
Pole, A., Department of Biochemistry and Molecular Medicine, S. O. M. A. H. S., Dimri, M., & P. Dimri, G. (2016) · AIMS Molecular Science · doi:10.3934/molsci.2016.3.300 · Cited by 155
“However, cancer cells may further exhibit redox adaptation resulting in drug resistance, which may require development of novel reagents that target redox adaptive response in cancer cells [156].”
BackgroundInfluentialPolier, G., Ding, J., Konkimalla, B. V., Eick, D., Ribeiro, N., Köhler, R., Giaisi, M., Efferth, T., Desaubry, L., Krammer, P. H., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.66 · Cited by 166
“Thus, tumors, particularly in advanced stage, produce elevated levels of reactive oxygen species and show an altered redox status.(22) This biochemical property of cancer cells can be exploited to achieve therapeutic activity and selectivity.”
BackgroundActivity-based fluorescence probes for pathophysiological peroxynitrite fluxes
Mao, Z., Xiong, J., Wang, P., An, J., Zhang, F., Liu, Z., & Seung Kim, J. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214356 · Cited by 165
Aithal, K. B., Kumar, S. M. R., Rao, N. B., Udupa, N., & Rao, S. B. S. (2009) · Cell Biology International · doi:10.1016/j.cellbi.2009.06.018 · Cited by 165
Gandhy, S. U., Kim, K., Larsen, L., Rosengren, R. J., & Safe, S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-564 · Cited by 164
“Increased ROS contributes to tumor formation due to several factors including oxidative DNA damage; however, several anticancer drugs also induce ROS and this plays an important role in their cancer chemotherapeutic activity [42,43].”
BackgroundPhotodynamic therapy and diagnosis: Principles and comparative aspects
Dobson, J., de Queiroz, G. F., & Golding, J. P. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2017.11.012 · Cited by 162
“Antioxidant defences that remove excess ROS are upregulated in many cancers (Tracootham et al. 2009), undermining the full potential of PDT. Combination of glycolysis inhibitors with PDT has been shown to deplete cellular antioxidants and significantly improve PDT cytotoxicity against human cancer…”
BackgroundLi, Z., Han, J., Yu, L., Qian, X., Xing, H., Lin, H., Wu, M., Yang, T., & Chen, Y. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201800145 · Cited by 165
Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications
Silva, M. P., Saraiva, L., Pinto, M. M. M., & Sousa, E. (2020) · Molecules · doi:10.3390/molecules25184323 · Cited by 168
“The 7-ethyl-10-boronic acid 47 (Scheme 10) was designed based on the fact that alkyl and aryl boronic acids are easily oxidized by hydrogen peroxide (H2O2) and that usually cancer cells have increased levels of reactive oxygen species (ROS), comparing to normal cells [49,50].”
BackgroundMechanisms of mTOR inhibitor resistance in cancer therapy
Carew, J. S., Kelly, K. R., & Nawrocki, S. T. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0167-8 · Cited by 161
“This report suggests that high levels of reactive oxygen species may also confer rapalog resistance [66].”
BackgroundDimethyl fumarate, a two‐edged drug: Current status and future directions
Saidu, N. E. B., Kavian, N., Leroy, K., Jacob, C., Nicco, C., Batteux, F., & Alexandre, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21567 · Cited by 160
Self-citationState-of-the-art advances of copper-based nanostructures in the enhancement of chemodynamic therapy
Hao, Y.-N., Zhang, W.-X., Gao, Y.-R., Wei, Y.-N., Shu, Y., & Wang, J.-H. (2021) · Journal of Materials Chemistry B · doi:10.1039/d0tb02360d · Cited by 161
Deubiquitinases as a Signaling Target of Oxidative Stress
Cotto-Rios, X. M., Békés, M., Chapman, J., Ueberheide, B., & Huang, T. T. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.11.011 · Cited by 159
“Although oxidative stress results in macromolecular damage and is implicated in various disease states, including atherosclerosis, diabetes (Paravicini and Touyz, 2006), neurodegeneration (Andersen, 2004), aging (Haigis and Yankner, 2010), and cancer (Trachootham et al., 2009), accumulating evidence indicates that ROS…”
BackgroundMetabolic Control by Heat Stress Determining Cell Fate to Ferroptosis for Effective Cancer Therapy
Xie, S., Sun, W., Zhang, C., Dong, B., Yang, J., Hou, M., Xiong, L., Cai, B., Liu, X., & Xue, W. (2021) · ACS Nano · doi:10.1021/acsnano.1c00380 · Cited by 163
Akhtar, M. J., Alhadlaq, H. A., Alshamsan, A., Khan, M. A. M., & Ahamed, M. (2015) · Scientific Reports · doi:10.1038/srep13876 · Cited by 171
Targeting Metabolic–Redox Circuits for Cancer Therapy
Wang, K., Jiang, J., Lei, Y., Zhou, S., Wei, Y., & Huang, C. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.01.001 · Cited by 162
MnO2-Based Nanomotors with Active Fenton-like Mn2+ Delivery for Enhanced Chemodynamic Therapy
Ou, J., Tian, H., Wu, J., Gao, J., Jiang, J., Liu, K., Wang, S., Wang, F., Tong, F., Ye, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c08926 · Cited by 158
Exploring silver nanoparticles for cancer therapy and diagnosis
Miranda, R. R., Sampaio, I., & Zucolotto, V. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112254 · Cited by 171
Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth
Schöckel, L., Glasauer, A., Basit, F., Bitschar, K., Truong, H., Erdmann, G., Algire, C., Hägebarth, A., Willems, P. H., Kopitz, C., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0138-0 · Cited by 161
“To prevent oxidative stress induction, cancer cells upregulate ROSdetoxifying systems [30, 45, 46], thereby, keeping the ROS level within its pro-tumorigenic range [14, 47].”
BackgroundCancer stem cells and cancer therapy
Soltanian, S., & Matin, M. M. (2011) · Tumor Biology · doi:10.1007/s13277-011-0155-8 · Cited by 159
“Moreover, expression of high levels of oxidative stress-responsive genes in CSCs could confer part of their ability to resist anticancer therapy [125, 126].”
BackgroundYonemori, S., & Ono, R. (2014) · Journal of Physics D: Applied Physics · doi:10.1088/0022-3727/47/12/125401 · Cited by 159
Kluza, J., Corazao-Rozas, P., Touil, Y. S., Jendoubi, M., Maire, C., Guerreschi, P., Jonneaux, A., Ballot, C., Balayssac, S., Valable, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0979 · Cited by 175
“Controlled production of ROS participates in the promotion and progression of melanoma (3), whereas higher ROS generation displays cell-damaging effects (4).”
BackgroundMitochondrial Sirtuins and Their Relationships with Metabolic Disease and Cancer
Kumar, S., & Lombard, D. B. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.6213 · Cited by 158
“As previously noted, elevated ROS promote carcinogenesis; however, excessive ROS levels beyond a toxic threshold may overwhelm cellular antioxidant capacity and trigger cell cycle arrest and apoptosis (161).”
Alizadeh, N., & Salimi, A. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00771-1 · Cited by 164
“ROS including hydrogen peroxide, superoxide anion, hydroxyl radical and singlet oxygen have the potential to kill cancer cells by destroying biomolecules such as DNA, proteins and lipids [99].”
BackgroundKhan, A. Q., Rashid, K., AlAmodi, A. A., Agha, M. V., Akhtar, S., Hakeem, I., Raza, S. S., & Shahab Uddin, M. S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112142 · Cited by 174
Liu, J., Bo, X., Zhao, Z., & Guo, L. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.06.042 · Cited by 161
“Nevertheless, over production and accumulation of ROS in cells could lead to a series of cell damage and cause aging and disease, including cardiovascular disease, Alzheimer's disease and cancer (Pagliari et al., 2012; Trachootham et al., 2009; Wu et al., 2011).”
BackgroundUnderstanding Cellular Redox Homeostasis: A Challenge for Precision Medicine
Tretter, V. E., Hochreiter, B., Zach, M. L., Krenn, K., & Klein, K. U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010106 · Cited by 170
“Newer approaches in anti-cancer therapies, however, also target the metabolism and immune surveillance fueling these cells [58].”
BackgroundRecent advances for enhanced photodynamic therapy: from new mechanisms to innovative strategies
Wang, X., Peng, J., Meng, C., & Feng, F. (2024) · Chemical Science · doi:10.1039/d3sc07006a · Cited by 178
Redox Regulation in Cancer Stem Cells
Ding, S., Li, C., Cheng, N., Cui, X., Xu, X., & Zhou, G. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/750798 · Cited by 167
“Because high antioxidant capacity enhances cell survival and impairs cellular responses to anticancer therapy [14], induction of ROS-mediated damage in cancer cells by proper pharmacological agents that either promote ROS generation beyond the cellular antioxidative capacity or disable the cellular antioxidant systemh…”
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress
Ketola, K., Hilvo, M., Hyötyläinen, T., Vuoristo, A., Ruskeepää, A.-L., Orešič, M., Kallioniemi, O., & Iljin, K. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.530 · Cited by 159
“Thus, cancer cells are vulnerable to acute induction of oxidative stress caused by agents inducing ROS or reducing antioxidative capacity (Khandrika et al, 2009; Trachootham et al, 2009; Acharya et al, 2010; Cairns et al, 2011).”
BackgroundCallaghan, S., & Senge, M. O. (2018) · Photochemical & Photobiological Sciences · doi:10.1039/c8pp00008e · Cited by 173
Guan, Q., Guo, R., Huang, S., Zhang, F., Liu, J., Wang, Z., Yang, X., Shuai, X., & Cao, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.048 · Cited by 162
Recent advances in MOF-based nanoplatforms generating reactive species for chemodynamic therapy
Zhong, Y., Li, X., Chen, J., Wang, X., Wei, L., Fang, L., Kumar, A., Zhuang, S., & Liu, J. (2020) · Dalton Transactions · doi:10.1039/d0dt01882a · Cited by 158
Sári, Z., Mikó, E., Kovàcs, T., Jankó, L., Csonka, T., Lente, G., Sebő, É., Tóth, J., Tóth, D., Árkosy, P., et al. (2020) · Cancers · doi:10.3390/cancers12092411 · Cited by 169
Role of the Keap1–Nrf2 Pathway in Cancer
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-420117-0.00008-6 · Cited by 158
“Of the numerous Nrf2 targets that have been shown to affect the sensitivity toROS-dependent cellular killing, those involved in GSH metabolism are likely to be central (Gorrini et al., 2013; Trachootham et al., 2009).”
BackgroundOck, C.-Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i4.302 · Cited by 149
Hirst, A. M., Frame, F. M., Arya, M., Maitland, N. J., & O’Connell, D. (2016) · Tumor Biology · doi:10.1007/s13277-016-4911-7 · Cited by 169
“One explanation may be the rapidly dividing nature of tumour cells, increasing their vulnerability to DNA damage in M-phase [50], and/or the different tolerances of normal and cancer cells to elevated ROS levels [25] as alluded to earlier.”
BackgroundVrettos, E. I., Mező, G., & Tzakos, A. G. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.80 · Cited by 176
Gong, F., Cheng, L., Yang, N., Jin, Q., Tian, L., Wang, M., Li, Y., & Liu, Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02933 · Cited by 157
Hydroxycinnamic acids and human health: recent advances
Coman, V., & Vodnar, D. C. (2019) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.10010 · Cited by 173
Gao, H., Cao, Z., Liu, H., Chen, L., Bai, Y., Wu, Q., Yu, X., Wei, W., & Wang, M. (2023) · Theranostics · doi:10.7150/thno.80887 · Cited by 162
“ROS can damage biological macromolecules such as lipids, proteins, and DNA, and thereby induce cancer cell apoptosis [6-8].”
BackgroundZhang, X., Wang, X., Wu, T., Li, B., Liu, T., Wang, R., Liu, Q., Liu, Z., Gong, Y., & Shao, C. (2015) · Scientific Reports · doi:10.1038/srep12579 · Cited by 165
Quantifying intracellular hydrogen peroxide perturbations in terms of concentration
Huang, B. K., & Sikes, H. D. (2014) · Redox Biology · doi:10.1016/j.redox.2014.08.001 · Cited by 152
“No competing financial interests exist.”
MethodInfluentialChiang, Y., Yen, Y.-W., & Lo, C.-L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.05.007 · Cited by 160
Davalli, P., Marverti, G., Lauriola, A., & D’Arca, D. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2389523 · Cited by 165
“Many cancer types may develop strong antioxidant mechanisms and maintain higher ROS levels than normal cells, but, at the same time, excessive OS levels may have tumor-suppressive effects [140].”
BackgroundMicro/Nanomaterials‐Augmented Hydrogen Therapy
Zhou, G., Goshi, E., & He, Q. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900463 · Cited by 153
Kaushik, N., Uddin, N., Sim, G. B., Hong, Y. J., Baik, K. Y., Kim, C. H., Lee, S., Kaushik, N. K., & Choi, E. H. (2015) · Scientific Reports · doi:10.1038/srep08587 · Cited by 159
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action
Campaner, E., Rustighi, A., Zannini, A., Cristiani, A., Piazza, S., Ciani, Y., Kalid, O., Golan, G., Baloglu, E., Shacham, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15772 · Cited by 146
Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
Ye, Q., Liu, K., Shen, Q., Li, Q., Hao, J., Han, F., & Jiang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00487 · Cited by 159
Shen, J., Rees, T. W., Ji, L., & Chao, H. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214016 · Cited by 159
Foundations of plasmas for medical applications
von Woedtke, T., Laroussi, M., & Gherardi, M. (2022) · Plasma Sources Science and Technology · doi:10.1088/1361-6595/ac604f · Cited by 170
Zhang, B., Duan, D., Ge, C., Yao, J., Liu, Y., Li, X., & Fang, J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5016507 · Cited by 161
Kowol, C. R., Heffeter, P., Miklos, W., Gille, L., Trondl, R., Cappellacci, L., Berger, W., & Keppler, B. K. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0864-x · Cited by 163
The role of thioredoxin system in cancer: strategy for cancer therapy
Jia, J., Geng, W.-S., Wang, Z.-Q., Chen, L., & Zeng, X. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03869-4 · Cited by 162
Impact of oxidative stress on telomere biology
Ahmed, W., & Lingner, J. (2018) · Differentiation · doi:10.1016/j.diff.2017.12.002 · Cited by 153
Bringing the heavy: carbon ion therapy in the radiobiological and clinical context
Schlaff, C. D., Krauze, A. V., Belard, A., O’Connell, J. J., & Camphausen, K. A. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-88 · Cited by 161
“radicals and reactive oxygen species [96-99].”
Reversible Fluorescent Probes for Biological Redox States
Kaur, A., Kolanowski, J. L., & New, E. J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506353 · Cited by 156
Wang, G., Zhang, T., Sun, W. Y., Wang, H., Yin, F., Wang, Z., Zuo, D., Sun, M., Zhou, Z., Lin, B., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.02.015 · Cited by 155
Inorganic Nanoparticles Applied as Functional Therapeutics
Liu, Q., Kim, Y., Im, G., Zhu, J., Wu, Y., Liu, Y., & Bhang, S. H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202008171 · Cited by 147
Shen, J., Yu, H., Shu, Y., Ma, M., & Chen, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202106106 · Cited by 153
Pathological neoangiogenesis depends on oxidative stress regulation by ATM
Okuno, Y., Nakamura-Ishizu, A., Otsu, K., Suda, T., & Kubota, Y. (2012) · Nature Medicine · doi:10.1038/nm.2846 · Cited by 152
Lu, W., Hu, Y., Chen, G., Chen, Z., Zhang, H., Wang, F., Feng, L., Pelicano, H., Wang, H., Keating, M. J., et al. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001326 · Cited by 151
Self-citationGong, K., & Li, W. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.09.018 · Cited by 159
“ROS generation is an importantmediator ofmany anti-cancer agents [48].”
BackgroundHuang, H., Zhang, S., Li, Y., Liu, Z., Mi, L., Cai, Y., Wang, X., Chen, L., Ran, H., Xiao, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24108-6 · Cited by 165
Design and Mechanism Insight of Monodispersed AuCuPt Alloy Nanozyme with Antitumor Activity
Liu, J., Dong, S., Gai, S., Dong, Y., Liu, B., Zhao, Z., Xie, Y. H., Feng, L., Yang, P., & Lin, J. (2023) · ACS Nano · doi:10.1021/acsnano.3c06833 · Cited by 153
The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review)
Wei, W., Lin, S., LIU, D.-L., & Wang, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2741 · Cited by 158
“This finding supports the notion that ROS manipulation strategy could be selective between cancerous and normal cells, as indicated by an increasing body of evidence (24,25).”
BackgroundROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies
Rinaldi, M., Caffo, M., Minutoli, L., Marini, H. R., Abbritti, R. V., Squadrito, F., Trichilo, V., Valenti, A., Barresi, V., Altavilla, D., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060984 · Cited by 167
“Superoxide dismutase (SOD), catalase, glutathione peroxidase, and peroxiredoxin are major intracellular ROS-scavenging enzymes [103].”
BackgroundMultifunctional AIEgens for Future Theranostics
Feng, G., & Liu, B. (2016) · Small · doi:10.1002/smll.201601637 · Cited by 151
Metabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells
Jagušt, P., de Luxán‐Delgado, B., Parejo-Alonso, B., & Sancho, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00203 · Cited by 154
Mitra, S., Anand, U., Jha, N. K., Shekhawat, M. S., Saha, S. C., Nongdam, P., Rengasamy, K. R. R., Proćków, J., & Dey, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772418 · Cited by 167
“Earlier reports suggest that enhancement of ROS production in glutathione antioxidant system disabled cancer cells, which further leads to apoptosis of such cancer cells (Trachootham et al., 2009).”
BackgroundHao, J., Ge, K., Chen, G., Dai, B., & Li, Y. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00356f · Cited by 150
Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C∧N-Chelated and Pyridine Ligands
Liu, Z., Romero‐Canelón, I., Habtemariam, A., Clarkson, G. J., & Sadler, P. J. (2014) · Organometallics · doi:10.1021/om500644f · Cited by 148
ROS-activated Anticancer Prodrugs: a New Strategy for tumor-specific Damage
Peng, X., & Gandhi, V. V. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.61 · Cited by 167
Targeting a cornerstone of radiation resistance: cancer stem cell.
Moncharmont, C., Lévy, A., Gilormini, M., Bertrand, G., Chargari, C., Alphonse, G., Ardail, D., Rodriguez-Lafrasse, C., & Magné, N. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.024 · Cited by 149
Antioxidant polyphenols in cancer treatment: Friend, foe or foil?
Russo, G. L., Tedesco, I., Spagnuolo, C., & Russo, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.05.005 · Cited by 157
Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer
Ju, H., Lu, Y.-X., Wu, Q.-N., Liu, J., Zeng, Z.-L., Mo, H.-Y., Chen, Y., Tian, T., Wang, Y., Kang, T.-B., et al. (2017) · Oncogene · doi:10.1038/onc.2017.227 · Cited by 159
Self-citationLiedtke, K. R., Bekeschus, S., Käding, A., Hackbarth, C., Kuehn, J., Heidecke, C.-D., von Bernstorff, W., von Woedtke, T., & Partecke, L. I. (2017) · Scientific Reports · doi:10.1038/s41598-017-08560-3 · Cited by 154
Cell-Penetrating Protein/Corrole Nanoparticles
Soll, M., Goswami, T. K., Chen, Q., Saltsman, I., Teo, R. D., Shahgholi, M., Lim, P. P., Bilio, A. J. D., Cohen, S., Termini, J. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38592-w · Cited by 148
Shi, Y., Zhang, J., Huang, H., Cao, C., Yin, J., Xu, W., Wang, W., Song, X., Zhang, Y., & Dong, X. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000005 · Cited by 151
SOD1, an unexpected novel target for cancer therapy.
Papa, L., Manfredi, G., & Germain, D. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.4 · Cited by 147
“Therefore, the observation that in the absence of SIRT3, the activity of SOD2 is abolished [38], is a likely reason for the elevated ROS levels in cancer cells [39].”
BackgroundMitochondrial membrane potential and reactive oxygen species in cancer stem cells
Zhang, B., Wang, D., Fen-fen, G., & Xuan, C. (2014) · Familial Cancer · doi:10.1007/s10689-014-9757-9 · Cited by 158
“ROS are involved in each stage of cancer development, including the initiation, promotion, and progression [39].”
BackgroundKurapati, R., Muzi, L., de Garibay, A. P. R., Russier, J., Voiry, D., Vacchi, I. A., Chhowalla, M., & Bianco, A. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201605176 · Cited by 147
LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective
Ciccarese, F., Zulato, E., & Indraccolo, S. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8730816 · Cited by 158
“A further increase in ROS levels induces extensive damage to cell structures and selective elimination of cancer cells, implying modulation of redox homeostasis as a promising anticancer strategy [88].”
BackgroundManivasagan, P., Joe, A., Han, H., Thambi, T., Selvaraj, M., Chidambaram, K., Kim, J., & Jang, E. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2021.100197 · Cited by 162
Mandal, P. K., Schneider, M., Kölle, P., Kuhlencordt, P., Förster, H., Beck, H., Bornkamm, G. W., & Conrad, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1509 · Cited by 145
Zou, P., Zhang, J., Xia, Y., Kanchana, K., Guo, G., Chen, W., Huang, Y., Wang, Z., Yang, S., & Liang, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3333 · Cited by 148
“Interestingly, cancer cells are more sensitive to rapid increases in ROS levels than normal cells[32].”
BackgroundWon, H. J., Ryplida, B., Kim, S. G., Lee, G., Ryu, J. H., & Park, S. Y. (2020) · ACS Nano · doi:10.1021/acsnano.0c02517 · Cited by 147
Bauer, G., & Graves, D. B. (2016) · Plasma Processes and Polymers · doi:10.1002/ppap.201600089 · Cited by 152
Applications of Light-Responsive Systems for Cancer Theranostics
Chen, H., & Zhao, Y. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b01114 · Cited by 149
Santulli, P., Chouzenoux, S., Fiorese, M., Marcellin, L., Lemarechal, H., Millischer, A.-E., Batteux, F., Borderie, D., & Chapron, C. (2015) · Human Reproduction · doi:10.1093/humrep/deu290 · Cited by 137
“In neoplastic conditions, the balance of ROS production controls tumour cell proliferation (Laurent et al., 2005; Alexandre et al., 2006; Trachootham et al., 2009; Gorrini et al., 2013), as well as the metastatic potential of tumour cells (Ishikawa et al., 2008).”
BackgroundFernandez, H. R., Gadre, S. M., Tan, M., Graham, G. T., Mosaoa, R., Ongkeko, M. S., Kim, K. A., Riggins, R. B., Parasido, E., Petrini, I., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-018-0101-z · Cited by 139
“We conclude that SLC25A1 is a key regulator of the sub-cellular compartmentalization of the citrate pools, enabling CSCs to utilize citrate for mitochondrial respiration and leading to the activation of IDH2-NADPH system to alleviate the harmful effects of ROS build-up.”
BackgroundInfluentialMollick, M. M. R., Rana, D. K., Dash, S. K., Chattopadhyay, S., Bhowmick, B., Maity, D., Mondal, D., Pattanayak, S., Roy, S., Chakraborty, M., et al. (2015) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2015.04.033 · Cited by 149
“Therefore, maintaining cellular ROS homeostasis is crucial for normal cell growth and survival (Trachootham et al., 2009).”
BackgroundGlutaminolysis and autophagy in cancer
Villar, V. H., Merhi, F., Djavaheri-Mergny, M., & Durán, R. V. (2015) · Autophagy · doi:10.1080/15548627.2015.1053680 · Cited by 143
Li, J., Ke, W., Wang, L., Huang, M., Yin, W., Zhang, P., Chen, Q., & Ge, Z. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.029 · Cited by 145
Induction of oxidative stress by anticancer drugs in the presence and absence of cells
Yokoyama, C., Sueyoshi, Y., Ema, M., Mori, Y., Takaishi, K., & Hisatomi, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.6931 · Cited by 163
“In particular, it can be the primary trigger and/or mediator of carcinogenesis by contributing to the initiation of cellular malignancy and the progression of cancer (8-10).”
Small mitochondria-targeting molecules as anti-cancer agents
Wang, F., Ogasawara, M. A., & Huang, P. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.12.003 · Cited by 142
Self-citationPereira, L., Igea, A., Canovas, B., Dolado, I., & Nebreda, A. R. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302732 · Cited by 138
“However, the pro ‐ tumourigenic effect of the accumulation of intracellular ROS can turn out to be a double ‐ edged sword, since high ROS levels may lower the apoptotic threshold for cytotoxicity (Trachootham et al, 2009; Wang & Yi, 2008).”
Hu, F., & Liu, B. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01414c · Cited by 143
The Role of Oxidative Stress in Tumorigenesis and Progression
Li, K., Deng, Z., Lei, C., Ding, X., Li, J., & Wang, C. (2024) · Cells · doi:10.3390/cells13050441 · Cited by 153
“…source, containing the endoplasmic reticulum, NADPH hydrogenase, and catalase, among which NOXs are considered as the central enzyme family for ROS production [6]; and an exogenous pathway including external factors such as radiation, chemotherapy, inflammatory factors, and air pollution [7].”
BackgroundAkbarzadeh, F. Z., Sarraf, M., Ghomi, E. R., Kumar, V. V., Salehi, M., Ramakrishna, S., & Bae, S. (2024) · Journal of Magnesium and Alloys · doi:10.1016/j.jma.2024.06.015 · Cited by 153
Metadata
- Authors
- Trachootham, D., Alexandre, J., & Huang, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Huang, Peng
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-05-29
- Volume
- 8
- Issue
- 7
- Pages
- 579-591
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972779889
- Cited by
- 5,452
- References
- 163
- Citations by year
- 2026: 322 · 2025: 332 · 2024: 340 · 2023: 372 · 2022: 421 · 2021: 462 · 2020: 444 · 2019: 454 · 2018: 393 · 2017: 404 · 2016: 341 · 2015: 289 · 2014: 282 · 2013: 204 · 2012: 158
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA085563, R01CA109041, CA109041, R01CA085563, R01CA100428, CA100428)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- reactive oxygen species, oxidative stress, redox modulation, cancer cells, drug resistance, antioxidant capacity, anticancer agents, genomic instability
- MeSH terms
- Adaptation, Physiological, Animals, Glutathione, Humans, Neoplasms, Oxidation-Reduction, Neoplastic Stem Cells, Reactive Oxygen Species, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.